Journal Article Cites HemoVoid™ in Etiology Study of Cancer-related Anemia
Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching the red cell proteome.

News Release

Journal Article Cites HemoVoid™ in Etiology Study of Cancer-related Anemia


MONMOUTH JUNCTION, NJ, February 6, 2020 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching the red cell proteome, in order to measure autoantibodies to band 3 protein in cancer patient erythrocytes.


The citation is:

Kitao, Akihito, et al. "Band 3 ectopic expression in colorectal cancer induces an increase in erythrocyte membrane-bound IgG and may cause immune-related anemia." International Journal of Hematology (2020): 1-10.


Autoimmune hemolytic anemia (AIHA) is a rare comorbidity in colorectal cancer (CRC) and has an unknown etiology. To better understand cancer-related anemia, the authors’ investigated ectopic band 3 expression and erythrocyte membrane-bound IgG in a CRC cohort. To reduce the interference from Hemoglobin, the article states “Erythrocytes were lysed … and hemoglobin was depleted using HemoVoid (Biotech Support Group, NJ, USA, Cat. No. HVK-10)”. The investigation concluded that anti-band 3 antibody was higher in the IgG fraction of CRC patients’ compared to that of healthy controls, and that red cell membrane-bound IgG in patients with CRC, may be clinically associated to cancer-related anemia.


Whole Blood Compartments

Through more efficient methods to measure the various blood components– red cells, white cells, platelets and plasma, we hope our products will contribute to understanding how these compartments cross-communicate. Those connections all play a role in normal homeostasis and in disease. This article illustrates how red cells react to IgG, and how this interaction plays a role in cancer-related anemia. For this purpose, I am pleased to see that our product HemoVoid™ was a necessary and efficient step to remove interferences from Hemoglobin in the Western blot analysis”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.


For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm


For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452




About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com


Contact:

Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com